27 In a recent real-world study, three cases with advanced iCCA with FGFR2 fusions or rearrangements received pemigatinib and showed a trend towards improved OS. 35 Treatment-related time toxicity has emerged as a relevant indicator of palliative treatment benefits in incurable diseases, including advanced cancers.
← all excerpts
Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases.
1
—
—